Burgers, fried chicken, pizza, and creamy sauces slow gastric transit even further, overwhelming a stomach already processing food more slowly
Before and after using needles: how our patients views changed Much of the conversation around GLP-1 treatments focuses on the fear of needles before treatment begins
On Monday morning, Novo Nordisk, the makers of the GLP-1 drug semaglutide (Ozempic and Wegovy), and Hims & Hers Health Inc
Safety across the full program was consistently favorable: adverse events, primarily mild headache and gastrointestinal symptoms, occurred at rates comparable to placebo, with no treatment-related discontinuations, no IGF-1 elevation, and no impact on glucose metabolism